DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer

被引:6
作者
Wang, Jieyu [1 ,2 ]
Li, Jun [1 ]
Chen, Ruifang [1 ]
Yue, Huiran [1 ]
Li, Wenzhi [1 ,2 ]
Wu, Beibei [1 ]
Bai, Yang [1 ]
Zhu, Guohua [1 ,2 ]
Lu, Xin [1 ,2 ]
机构
[1] Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol, 128 Shenyang Rd, Shanghai 200090, Peoples R China
[2] Fudan Univ, Shanghai Key Lab Female Reprod Endocrine Related, Shanghai, Peoples R China
基金
上海市自然科学基金; 中国国家自然科学基金;
关键词
Ovarian cancer; High-grade serous ovarian cancer; DNA profiling; Methylation subtypes; Prognosis; EXPRESSION; GENE; CLASSIFICATION; ASSOCIATION; RESISTANCE; SIGNATURES; METHYLOME; DIAGNOSIS; PATTERNS;
D O I
10.1186/s13148-021-01178-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High-grade serous ovarian cancer (HGSOC) is the most common type of epigenetically heterogeneous ovarian cancer. Methylation typing has previously been used in many tumour types but not in HGSOC. Methylation typing in HGSOC may promote the development of personalized care. The present study used DNA methylation data from The Cancer Genome Atlas database and identified four unique methylation subtypes of HGSOC. With the poorest prognosis and high frequency of residual tumours, cluster 4 featured hypermethylation of a panel of genes, which indicates that demethylation agents may be tested in this group and that neoadjuvant chemotherapy may be used to reduce the possibility of residual lesions. Cluster 1 and cluster 2 were significantly associated with metastasis genes and metabolic disorders, respectively. Two feature CpG sites, cg24673765 and cg25574024, were obtained through Cox proportional hazards model analysis of the CpG sites. Based on the methylation level of the two CpG sites, the samples were classified into high- and low-risk groups to identify the prognostic information. Similar results were obtained in the validation set. Taken together, these results explain the epigenetic heterogeneity of HGSOC and provide guidance to clinicians for the prognosis of HGSOC based on DNA methylation sites.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling
    Bashashati, Ali
    Ha, Gavin
    Tone, Alicia
    Ding, Jiarui
    Prentice, Leah M.
    Roth, Andrew
    Rosner, Jamie
    Shumansky, Karey
    Kalloger, Steve
    Senz, Janine
    Yang, Winnie
    McConechy, Melissa
    Melnyk, Nataliya
    Anglesio, Michael
    Luk, Margaret T. Y.
    Tse, Kane
    Zeng, Thomas
    Moore, Richard
    Zhao, Yongjun
    Marra, Marco A.
    Gilks, Blake
    Yip, Stephen
    Huntsman, David G.
    McAlpine, Jessica N.
    Shah, Sohrab P.
    JOURNAL OF PATHOLOGY, 2013, 231 (01) : 21 - 34
  • [22] Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer
    Freimund, Alison E.
    Beach, Jessica A.
    Christie, Elizabeth L.
    Bowtell, David D. L.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2018, 32 (06) : 983 - +
  • [23] AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer
    Hojnik, Marko
    Suster, Natasa Kenda
    Smrkolj, Spela
    Sisinger, Damjan
    Grazio, Snjezana Frkovic
    Verdenik, Ivan
    Rizner, Tea Lanisnik
    CANCERS, 2022, 14 (03)
  • [24] The Effect of WT-1 Positivity on Survival Outcomes in Patients with High-grade Serous Epithelial Ovarian Cancer
    Karakas, Sema
    Tunca, Aysun Fendal
    Altinay, Serdar
    Yildiz, Gunes Ozlem
    Ekin, Murat
    MEDICAL JOURNAL OF BAKIRKOY, 2022, 18 (02) : 151 - 156
  • [25] Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer
    Silva, Romina
    Glennon, Kate
    Metoudi, Michael
    Moran, Bruce
    Salta, Sofia
    Slattery, Karen
    Treacy, Ann
    Martin, Terri
    Shaw, Jacqui
    Doran, Peter
    Lynch, Lydia
    Jeronimo, Carmen
    Perry, Antoinette S.
    Brennan, Donal J.
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (01) : 120 - 132
  • [26] Identification of a four-gene methylation biomarker panel in high-grade serous ovarian carcinoma
    Baranova, Ivana
    Kovarikova, Helena
    Laco, Jan
    Sedlakova, Iva
    Vrbacky, Filip
    Kovarik, Dalibor
    Hejna, Petr
    Palicka, Vladimir
    Chmelarova, Marcela
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2020, 58 (08) : 1332 - 1340
  • [27] Integrated Analysis To Identify Molecular Biomarkers Of High-Grade Serous Ovarian Cancer
    Si, Manfei
    Zhang, Junji
    Cao, Jianzhong
    Xie, Zhibo
    Shu, Shan
    Zhu, Yapei
    Lang, Jinghe
    ONCOTARGETS AND THERAPY, 2019, 12 : 10057 - 10075
  • [28] The peritoneal tumour microenvironment of high-grade serous ovarian cancer
    Leinster, D. Andrew
    Kulbe, Hagen
    Everitt, Gemma
    Thompson, Richard
    Perretti, Mauro
    Gavins, Felicity N. E.
    Cooper, Dianne
    Gould, David
    Ennis, Darren P.
    Lockley, Michelle
    McNeish, Iain A.
    Nourshargh, Sussan
    Balkwill, Frances R.
    JOURNAL OF PATHOLOGY, 2012, 227 (02) : 136 - 145
  • [29] Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer
    Li-yuan Feng
    Bing-bing Yan
    Yong-zhi Huang
    Li Li
    Clinical Epigenetics, 2021, 13
  • [30] WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells
    Yu, Hai-Lan
    Ma, Xu-Dong
    Tong, Jin-Fei
    Li, Jian-Qiong
    Guan, Xiao-Jing
    Yang, Jian-Hua
    ONCOTARGETS AND THERAPY, 2019, 12 : 6191 - 6201